BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/15/2016 3:38:00 PM | Browse: 1272 | Download: 1841
 |
Received |
|
2016-01-26 08:58 |
 |
Peer-Review Started |
|
2016-01-27 12:57 |
 |
To Make the First Decision |
|
2016-03-07 09:31 |
 |
Return for Revision |
|
2016-03-08 09:46 |
 |
Revised |
|
2016-03-18 17:16 |
 |
Second Decision |
|
2016-03-22 17:36 |
 |
Accepted by Journal Editor-in-Chief |
|
2016-03-22 19:52 |
 |
Accepted by Executive Editor-in-Chief |
|
2016-03-30 17:07 |
 |
Articles in Press |
|
2016-03-30 17:07 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-07-01 16:22 |
 |
Publish the Manuscript Online |
|
2016-07-15 15:38 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Prospective Study |
Article Title |
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Amalia Azzariti, Letizia Porcelli, Oronzo Brunetti, Marzia Del Re, Vito Longo, Patrizia Nardulli, Michele Signorile, Jian-Ming Xu, Angela Calabrese, Anna Elisa Quatrale, Evaristo Maiello, Vito Lorusso and Nicola Silvestris |
Funding Agency and Grant Number |
|
Corresponding Author |
Nicola Silvestris, MD, Medical Oncology Unit, National Cancer Research Centre Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65, 70124 Bari,
Italy. n.silvestris@oncologico.bari.it |
Key Words |
Bevacizumab; Vascular endothelial growth factor; Angiopoietin 2; Metastatic colorectal cancer; Biomarker; Predictive factor |
Core Tip |
In the main topic of the identification of possible reliable markers to predict response to anti-angiogenic therapy, our paper represents an original contribution describing the role of not bevacizumab (BV)-bound vascular endothelial growth factor (VEGF)/total VEGF ratio and of bevacizumab serum level as predictors of response in a consecutive series of patients with metastatic colorectal cancer. In this paper the rediscovery of the predictive role of traditional biomarkers as not BV-bound VEGF/total VEGF plasma ratio together with the results of the bevacizumab pharmacokinetic in response, stable disease and progression settings of patients with metastatic colorectal cancer treated with bevacizumab plus oxaliplatin based chemotherapy supported our hypothesis.
|
Publish Date |
2016-07-15 15:38 |
Citation |
Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295 |
URL |
http://www.wjgnet.com/1007-9327/full/v22/i27/6287.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v22.i27.6287 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345